ADA: Hengrui, Innovent’s Incretins Shine In China Obesity Studies
Potential Comparative Advantages?
Positive clinical outcomes for Hengrui and Innovent/Lilly’s obesity candidates presented at ADA were based on trials that enrolled Chinese subjects and were characterized by fewer women and less severe obesity than similar Western studies. Even so, some of the data appear to stack up well against western rival drugs.
